To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Laboratory | Biodetection | Mass spectrometry
The mission of the Technological Innovations for Detection and Diagnosis Laboratory (LI2D), based on the CEA site of Marcoule, is to develop methodologies and technologies for the detection of pathogens or toxic substances found in the environment or in biological samples / tissues and the discovery and validation of biomarkers for diagnosis. The aim of his research is to support the regional and national industrial fabric by promoting the transfer of innovations and reagents.
The research carried out at Li2D is based on his expert knowledge in microbiological, immunological, genetic, genomic, proteomic, bioinformatics and high-resolution mass spectrometry techniques. This leads to the creation of reagents for targeted detection, such as monoclonal or polyclonal antibodies, for the development of rapid immunoassays (test strips or "detector tickets") or enzyme-linked immunosorbent assays (ELISA). For example, rapid assays have been designed for the detection of toxic marine algae, highly pathogenic bacteria, and more recently, Li2D has developed the Ebola eZYSCREEN® for rapid diagnosis in the field of Ebola virus. Probes and nucleotide primers development provides the development of specific and high-sensitivity detection assays (qPCR) based on the amplification of nucleotide sequences of the genome of microorganisms. The laboratory conducts these research to the pre-industrial stage. In the field of diagnosis without a priori in microbiology, researchers of Li2D recently proposed a new technology, phylopeptidomic, allowing the quick identification of all pathogenic biological agents in mixture and to quantify by high resolution mass spectrometry. The potential of this technology has been validated in national exercises aimed at the identification of highly pathogenic microorganisms in complex environments. The mastery of high-resolution mass spectrometry technologies for the analysis of proteins and massive sequencing approaches of genomes has also provided the development of new concepts of proteogenomics and opens the possibility of several applications including the analysis of complex microbiota.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.